- Report
- April 2024
- 30 Pages
Global
From €3157EUR$3,250USD£2,697GBP
- Report
- February 2024
- 150 Pages
Global
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 150 Pages
Global
From €4613EUR$4,750USD£3,941GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1457EUR$1,500USD£1,245GBP
From €6313EUR$6,500USD£5,393GBP
- Report
- January 2024
- 189 Pages
Global
From €7284EUR$7,500USD£6,223GBP
- Report
- August 2023
- 145 Pages
Global
From €3059EUR$3,150USD£2,614GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 80 Pages
Europe
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 90 Pages
Middle East, Africa
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 70 Pages
North America
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 70 Pages
Europe
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2024
- 70 Pages
United States
From €4613EUR$4,750USD£3,941GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4613EUR$4,750USD£3,941GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4613EUR$4,750USD£3,941GBP
- Report
- August 2023
- 150 Pages
North America
From €4613EUR$4,750USD£3,941GBP
- Report
- February 2021
- 500 Pages
United States
From €2331EUR$2,400USD£1,991GBP
Farxiga is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. Farxiga is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Farxiga is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to help regulate hormones and metabolism, and can be taken orally or injected.
Companies in the Farxiga market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more